Kristin D. Ripperger, Pharm.D. Candidate
University of Missouri-Kansas City School of Pharmacy at MU, Columbia, Missouri
Available options are limited for patients with neutropenia needing to be initiated or maintained on clozapine therapy. A common strategy that is often utilized in these patients is the use of lithium as augmentation to clozapine, which enables the health care provider a means of continuing or initiating clozapine therapy. Clozapine is the most effective antipsychotic based on data from the U.S. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)1 and the UK Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)2, but comes with the associated risk of neutropenia. This article reviews unique aspects of using lithium as an augmentation to clozapine, as well as other strategies that can be considered for maintaining or initiating clozapine therapy in patients with neutropenia.
Read More: Clozapine Induced Neutropenia